|
| 君实生物-U(688180)限售解禁 | | 解禁日期 | 本期流通股本
(万股) | 本期流通股本占
总股本比例(%) | 已流通股本
(万股) | 未流通股本
(万股) | 流通A股
(万股) | 流通A股占
总股本比例(%) | 限售股类型 | | 2025-07-07 | 184.52 | 0.19% | 98568.99 | 0.00 | 76454.90 | 77.56% | 股权激励期权行权 | | 2024-06-17 | 171.15 | 0.17% | 98384.47 | 184.52 | 50381.78 | 51.11% | 股权激励期权行权 | | 2024-01-02 | 25901.96 | 26.28% | 98213.32 | 355.67 | 50381.78 | 51.11% | 首发原股东限售股份 | | 2023-11-02 | 121.95 | 0.12% | 72311.35 | 26257.63 | 50259.83 | 50.99% | 股权激励期权行权 | | 2023-06-02 | 7000.00 | 7.10% | 72189.40 | 26379.58 | 43259.83 | 43.89% | 定向增发机构配售股份 | | 2023-02-07 | 281.82 | 0.29% | 65189.40 | 33379.58 | 43259.83 | 43.89% | 股权激励一般股份 | | 2022-11-07 | 26.97 | 0.03% | 64907.58 | 26379.58 | 42978.01 | 47.08% | 股权激励一般股份 | | 2022-07-15 | 180.18 | 0.20% | 64880.61 | 26379.58 | 42951.04 | 47.06% | 首发战略配售股份 |
|